Literature DB >> 10634375

Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males.

J D Wallace1, R C Cuneo, P A Lundberg, T Rosén, J O Jørgensen, S Longobardi, N Keay, L Sacca, J S Christiansen, B A Bengtsson, P H Sönksen.   

Abstract

To examine the interactions between acute exercise and GH on markers of bone and collagen turnover and to assess the potential for detecting GH abuse in athletes using these markers, we studied 17 aerobically trained males (age, 26.9+/-1.5 yr). Sequential studies of exercise, GH administration, and GH withdrawal were undertaken. A randomized, controlled study of rest vs. exercise showed that exercise did not change serum osteocalcin; other markers of formation increased transiently (each P<0.001): bone-specific alkaline phosphatase (+16.1%), carboxyterminal propeptide of type I procollagen (+14.1%), and procollagen III N-terminal extension peptide (+5.0%). The carboxyterminal cross-linked telopeptide of type I collagen, a bone resorption marker, increased 9.7% (P = 0.018) in response to exercise. A randomized, double blind, placebo-controlled, parallel study of recombinant human GH treatment (0.15 IU/kg x day) for 1 week increased serum osteocalcin (net increase preexercise, +/-10.0%; P = 0.017), carboxyterminal propeptide of type I procollagen (+17.6%; P = 0.002), procollagen III N-terminal extension peptide (+48.4%; P = 0.001), and carboxyterminal cross-linked telopeptide of type I collagen (53.3%; P = 0.009). Disappearance half-times after cessation of recombinant human GH for pre- and postexercise markers ranged from 248-770 h. We conclude 1) endurance exercise transiently activates bone and collagen turnover; 2) brief GH administration results in similar but quantitatively greater augmentation; and 3) these data will assist in designing a GH detection strategy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10634375     DOI: 10.1210/jcem.85.1.6262

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  33 in total

1.  Problems with GH doping in sports.

Authors:  M Bidlingmaier; Z Wu; C J Strasburger
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

2.  A follow-up of GH-dependent biomarkers during a 6-month period of the sporting season of male and female athletes.

Authors:  A Sartorio; M Jubeau; F Agosti; N Marazzi; A Rigamonti; E E Müller; N A Maffiuletti
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

Review 3.  Human growth hormone doping in sport.

Authors:  M Saugy; N Robinson; C Saudan; N Baume; L Avois; P Mangin
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

4.  Short-term bone biochemical response to a single bout of high-impact exercise.

Authors:  Timo Rantalainen; Ari Heinonen; Vesa Linnamo; Paavo V Komi; Timo E S Takala; Heikki Kainulainen
Journal:  J Sports Sci Med       Date:  2009-12-01       Impact factor: 2.988

5.  Serum prolidase activity in idiopathic and ischemic cardiomyopathy patients.

Authors:  Yusuf Sezen; Memduh Bas; Halil Altiparmak; Ali Yildiz; Hakan Buyukhatipoglu; Omer Faruk Dag; Zekeriya Kaya; Nurten Aksoy
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 6.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

7.  Response of bone metabolism related hormones to a single session of strenuous exercise in active elderly subjects.

Authors:  L Maïmoun; D Simar; D Malatesta; C Caillaud; E Peruchon; I Couret; M Rossi; D Mariano-Goulart
Journal:  Br J Sports Med       Date:  2005-08       Impact factor: 13.800

8.  Cortical bone resorption during exercise is interleukin-6 genotype-dependent.

Authors:  Sukhbir S Dhamrait; Laurence James; David J Brull; Saul Myerson; Emma Hawe; Dudley J Pennell; Michael World; Stephen E Humphries; Fares Haddad; Hugh E Montgomery
Journal:  Eur J Appl Physiol       Date:  2002-12-24       Impact factor: 3.078

9.  Osteocalcin as a negative regulator of serum leptin concentration in humans: insight from triathlon competitions.

Authors:  Amelia Guadalupe-Grau; Ignacio Ara; Cecilia Dorado; German Vicente-Rodríguez; Jorge Perez-Gomez; Javier Chavarren Cabrero; José A Serrano-Sanchez; Alfredo Santana; Jose A L Calbet
Journal:  Eur J Appl Physiol       Date:  2010-06-24       Impact factor: 3.078

10.  N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone.

Authors:  Shalender Bhasin; E Jiaxiu He; Miwa Kawakubo; E Todd Schroeder; Kevin Yarasheski; Gregory J Opiteck; Alise Reicin; Fabian Chen; Raymond Lam; Jeffrey A Tsou; Carmen Castaneda-Sceppa; Ellen F Binder; Stanley P Azen; Fred R Sattler
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.